Page 1,621«..1020..1,6201,6211,6221,623..1,6301,640..»

Company Spotlight: Cellect Biotechnology – RTTNews – RTT News

Posted: April 1, 2017 at 8:45 am

Shares of Cellect Biotechnology Ltd. (APOP) are up more than 44% over the last 5 trading days.

With its shares currently traded on both the NASDAQ and Tel Aviv Stock Exchange, Cellect is the company behind ApoGraft, a breakthrough technology for the isolation of stem cells from any given tissue.

Cellect's ApoGraft technology is aiming to turn stem cell transplants into a simple, safe and cost effective process, reducing the associated severe side effects, such as rejection and many other risks, such as Graft versus Host Disease.

Graft versus Host Disease, a condition in which the transplanted immune cells attack the recipient's cells, is a common complication associated with *allogeneic stem cell transplantation. (*Allogeneic stem cell transplantation involves transferring the stem cells to the recipient from a genetically matched relative or other donor).

The positive results from a clinical trial of ApoGraft that involved 104 healthy donors of blood stem cells reported in February of this year demonstrated that Cellect's ApoGraft is a safe, robust and reproducible process for clinical use.

According to the company, the use of the ApoGraft to process human stem cells for bone marrow transplantation resulted in a significant increase in the death of mature immune cells, primarily T Lymphocytes, without compromising the quantity and quality of stem cells. The process takes only a few hours as compared to days of complex and expansive lab work with traditional methods, is anticipated to be extremely cost effective in comparison to current approaches, and has the potential to significantly reduce the risk of GvHD.

The first blood cancer patient was treated in a phase I/II trial of ApoGraft in February of this year, and on March 27th, the company announced that the first stem cell transplant procedure has been successfully performed.

With the first stem cell transplant procedure being successful, Cellect has received the go-ahead from the independent Data and Safety Monitoring Board for enrolling additional 2 cancer patients for ApoGraft transplantation treatments.

The study is designed to enroll 12 patients.

Key Financials:

- Net loss for the fourth quarter ended December 31, 2016 was $0.75 million or $0.007 per share compared to a net loss of $0.96 million or $0.012 per share in Q4, 2015.

- Cash totaled $8.0 million at December 31, 2016 compared to $3.1 million on December 31, 2015.

- The number of shares outstanding is 107.58 million (Data sourced from Yahoo Finance).

In order to maximize the value of the Company for all stakeholders, Cellect plans to delist from the Tel Aviv Stock Exchange (TASE) in accordance with section 350 to the Israeli Company Law.

Shares of Cellect Biotechnology touched an all-time intra-day high of $13.50 on Mar.27, 2017 on the NASDAQ. The stock closed yesterday's trading at $8.98, up 2.75%.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Read more:
Company Spotlight: Cellect Biotechnology - RTTNews - RTT News

Posted in Biotechnology | Comments Off on Company Spotlight: Cellect Biotechnology – RTTNews – RTT News

The stem cell therapies offered by this La Jolla clinic aren’t FDA approved, may not work and cost $15000 – Los Angeles Times

Posted: April 1, 2017 at 8:44 am

Jim Durgeloh, 59, was desperate to avoid surgery. After a career as a construction contractor and hours of leisure time spent on a motorcycle around his Longview, Wash., home, he was facing an operation to replace his left hip.

Thats pretty invasive, he said, nervous about a surgery that would require being cut open and implanted with an artificial hip; Jims brother had died from complications after a similar operation. In the search for an alternative, he and his wife, Janet, happened upon the website for La Jolla-based StemGenex Medical Group, which touts itself as the worlds first and only Stem Cell Center of Excellence.

But what caught the Durgelohs attention were the words of Rita Alexander, its chief administrative officer and a founder.

Alexander wrote that she had suffered debilitating rheumatoid arthritis until a stem cell treatment sent her into remission. Today it remains my passion to advocate for those diagnosed with debilitating illnesses to have access to cutting edge stem cell treatment, she wrote.

Rita was very inspiring, Janet Durgeloh says.

Durgelohs doctor in Washington was skeptical about the therapy offered by StemGenex. He didnt think it was going to work, Durgeloh says. The therapy isnt approved by the Food and Drug Administration, which says such treatments are not based on scientific evidence and can be unsafe. Then there was the cost: about $15,000, not including airfare. That wasnt covered by Durgelohs insurance, which would have paid for his hip replacement.

But on a recent Wednesday morning, the Durgelohs were at the DoubleTree hotel in Del Mar, where their bill was paid by StemGenex. Durgeloh was still wearing a bandage on his midriff, where a StemGenex doctor had performed liposuction to obtain stem cells that subsequently were reinjected into his body, ostensibly to regenerate his damaged bones and tissues. They were preparing to fly home, infused with the hope communicated by the clinic staff, who seemed very optimistic, Durgeloh told me.

A lawsuit in San Diego federal court suggests that StemGenex may have given the Durgelohs nothing but hope. Three StemGenex patients two with diabetes and one with lupus say they were misled by the medical groups marketing pitch to pay $14,900 each in 2015 and 2016 for therapies that have had no effect.

The lawsuit, which seeks class-action status, claims that StemGenex has made its money by targeting the ill and the elderly with false, fabricated and purposefully misleading claims about patient satisfaction. Selena Moorer, a lupus patient from Florida, and her two co-plaintiffs say StemGenex has no reasonable basis for its marketing claim that the Stem Cell Treatments were effective to treat diseases as advertised. The lawsuit names StemGenex, Alexander and Andre Lallande, the groups chief medical officer, as defendants. The company denies the claims made in the lawsuit.

Durgelohs treatment was typical of the procedures offered as stem cell therapy. He says he received injections directly into his hips, his ailing knees and his back, with whatever was left over suffused into his body via an IV drip.

Whats most important to know is that theres no accepted scientific evidence that treatments using cells from adipose fat tissue layers work.

But as we reported last year, many clinics offering the treatments capitalize on the publics impression that stem cells have become some sort of medical miracle. Dr. Mehmet Oz warned his vast television audience about this misconception in February, when he aired a lengthy undercover investigation of stem cell clinics and called for government regulation. StemGenex wasnt mentioned in the piece.

StemGenex, in its reply to the Moorer lawsuit, asserts that the plaintiffs cannot prove that its representations regarding the efficacy of its stem cell treatments are actually false. The plaintiffs, it continues, do not cite to a single scientific study that disproves [StemGenexs] advertised claims.

StemGenex may not have to prove that in a court of law, but thats not the way federal regulation works. At nearly $15,000 a pop, the companies should have to show a treatment works.

The FDA has been grappling with this very point in pondering how to regulate the burgeoning industry. There are more than 500 clinics offering stem cell treatments in the U.S., according to a survey released last year by stem cell scientist Paul Knoepfler of UC Davis and bioethicist Leigh Turner of the University of Minnesota.

Right now, theres no consensus how these clinics should be regulated.

In 2015, UC San Diego researchers described stem cell treatment as medicines Wild West. As Hermes Taylor-Weiner and Joshua Graff Zivin observed, Because FDA guidelines are ambiguous, stem-cell clinics have in effect been operating without regulation.

The proliferation of the clinics has forced the FDA to take a closer look.

The government agency maintains that using stem cells extracted from a patients fat requires licensing as a drug, device or biological product, which means the clinics have to demonstrate the products are safe and effective, possibly via a clinical trial.

The clinics obviously disagree. Steven Brody, chief scientific officer of StemGenex, testified at an FDA hearing in September that if the FDA took a hands-off approach, this would help our patients have access to stem cell therapies.

Earlier this month, the New England Journal of Medicine reported the devastating outcome for three elderly women injected with fat-derived stem cells directly into their eyeballs by a clinic in Florida as a treatment for macular degeneration. The treatment left the patients totally or mostly blind.

Stem cell clinics typically are cagey about what patients should expect. They neither claim their treatments are effective nor explicitly state that theyre unfounded, Taylor-Weiner and Zivin observed. Their language is intentionally imprecise and exploits the vulnerability of patients with debilitating diseases.

Indeed, a disclaimer on the StemGenex home page states, Stem cell therapy is not FDA approved, and, StemGenex Medical Group and affiliates do not claim that treatment using autologous stem cells are a cure for any condition, disease, or injury.

Thats a striking admission for a treatment costing nearly $15,000 out-of-pocket and might help explain why health insurers shun the treatments.

The emotional video testimonials from patients posted on the StemGenex website carry disclaimers that the results experienced by those patients may not be typical or expected. You should not expect to experience these results.

When I asked Jamie Schubert, a StemGenex spokeswoman, to point me to a scientific study or any other evidence that its treatments work, she replied that anecdotal feedback from patients indicates that their symptoms have improved and their quality of life has increased.

There are other red flags. One of the medical groups physicians, plastic surgeon Scott Sessions, was placed on three years probation by the California Medical Board in February. He was accused of negligence related to cosmetic surgery and other procedures he performed on two patients at an unrelated facility in 2011 and 2013.

Schubert told me Wednesday that Dr. Sessions has informed us that he is in compliance with all requirements of the probationary terms of the medical board. But the very next day, his name, photograph and bio had disappeared from the StemGenex website. Sessions didnt respond to a request for comment.

The same thing happened with the logo of the American Board of Surgery, which had been prominently displayed on the StemGenex site, implying the company had the certification boards seal of approval. After I mentioned to Schubert that a board official told me that display was a complete misuse of our logo, it vanished. Schubert called it an error.

Peoples health needs are not suitable for unregulated Wild West experimentation, and anecdotal feedback isnt proof that cutting edge treatments are safe and effective. The course couldnt be clearer for the FDA and state medical regulators across the country: If these stem cell clinics are endangering their customers health and draining their pocketbooks for quack remedies, shut them down.

Keep up to date with Michael Hiltzik. Follow @hiltzikm on Twitter, see his Facebook page, or email michael.hiltzik@latimes.com.

Return to Michael Hiltzik's blog.

Link:
The stem cell therapies offered by this La Jolla clinic aren't FDA approved, may not work and cost $15000 - Los Angeles Times

Posted in Cell Medicine | Comments Off on The stem cell therapies offered by this La Jolla clinic aren’t FDA approved, may not work and cost $15000 – Los Angeles Times

Wake Forest Institute for Regenerative Medicine will lead $20 million project – Winston-Salem Journal

Posted: April 1, 2017 at 8:44 am

The Wake Forest Institute for Regenerative Medicine and a nonprofit it founded will undertake a five-year, $20 million project to apply advanced manufacturing to regenerative medicine, a process that will speed up the availability of replacement tissues and organs to patients.

Dr. Anthony Atala, the institutes director, talked about the project Friday during a program celebrating its launch at the institutes Biotech Place Atrium at 575 N. Patterson Ave. in downtown Winston-Salem. About 100 people attended the event.

A public-private partnership that involves the U.S. Army Medical Research and Materiel Command awarded the project, the institute said in a statement. The partnership, known as the Medical Technology Enterprise Consortium, awarded $10 million for projects that the Wake Forest institute will perform.

The institute has founded a nonprofit organization to conduct research to advance regenerative medicine manufacturing, the RegenMed Development Organization, which also is the recipient of a $10 million award from the consortium.

Today, we are launching this program of manufacturing to bring regenerative technologies to a broader audience, Atala said to reporters before the program started. We have been working on these projects in regenerative medicine for a number of years.

Now, this is basically a way to accelerate the manufacturing of these technologies to automate the process here. The goal is to stop making these systems by hand one at a time, but to automate the process, so we can scale it up and make the process more affordable so we can get it to patients faster.

The institute, which has 450 scientists collaborating on regenerative medicine research, will focus on two aspects of the project, Atala said. One is to develop standardized bioinks, which is what we use for our printing system. They are biological inks to allow us print tissues, he said.

Researchers with the institute use printers to apply living cells onto biodegradable structures that allow for tissue regeneration inside the body.

For us, at the end of the day this is about one thing how we can best deliver these technologies to our patients, Atala said.

The institute also will focus on developing standardized cell culture media liquids that support cell growth. These products are used in most regenerative medicine projects because of the billions of cells that must be grown for each patient, the institute said in a statement.

We have been spending many years now working on technologies that we re-create tissues and organs in laboratories, and weve been putting these tissues into our patients, Atala said. Now, the next step is how we can we manufacture these tissues on a large scale and provide these tissues to patients all over the country and all over the world.

During the program, retired Army Maj. Gen. Lester Martinez-Lopez told the audience that developing regenerative medicine with advanced manufacturing will help injured U.S. military personnel.

We are going to speed up the production process, said Martinez-Lopez, the president and chairman of the MTEC board. Its about delivering (tissues and organs) to that soldier, sailor, airman and Marine. Thats a big deal.

Doug Edgeton, the president and chief executive of the N.C. Biotechnology Center, said the project will add to the economic base of the Triad and North Carolina. The states life science industry represents $86 billion yearly in economic activity in North Carolina and $2.2 billion in state and local tax revenue, he said.

You all are doing a lot of good things here, Edgeton said to the audience.

After the program, Winston-Salem Mayor Allen Joines said the institutes project will generate jobs locally.

I can see companies coming in and creating jobs and creating jobs within the institute itself, Joines said. It will be a huge impact.

See the article here:
Wake Forest Institute for Regenerative Medicine will lead $20 million project - Winston-Salem Journal

Posted in Cell Medicine | Comments Off on Wake Forest Institute for Regenerative Medicine will lead $20 million project – Winston-Salem Journal

Cord Blood Association Names STEM CELLS Translational … – PR Web (press release)

Posted: April 1, 2017 at 8:44 am

Durham, NC (PRWEB) March 31, 2017

AlphaMed Press and the Cord Blood Association (CBA) are pleased to announce that STEM CELLS Translational Medicine (SCTM) is now the associations official journal. With this partnership, SCTM will launch a new journal section dedicated to cord blood research.

We are delighted to initiate this partnership with the Cord Blood Association, said Anthony Atala, M.D., Editor-in-Chief of STEM CELLS Translational Medicine and Director of the Wake Forest Institute for Regenerative Medicine. With this new journal section, SCTM further expands the scope of new research reports for our readers with the potential to accelerate progress in regenerative medicine.

CBA is an international nonprofit organization that promotes the work of the cord blood community for the purpose of saving lives, improving health, and changing medicine. The association is the first to join together public and private banks toward a common mission to advocate for cord blood use in order to expand its potentials in cell therapies and regenerative medicine, and to also jointly advocate for global regulations that will allow use of cord blood and cord tissues in medical applications.

SCTM is an international peer-reviewed journal, publishing articles focused on advancing the clinical utilization of stem cell molecular and cellular biology. By bridging stem cell research and helping speed translations of emerging lab discoveries into clinical trials, SCTM will help move applications of these critical investigations closer to accepted best practices and ultimately improve outcomes.

SCTM provides a platform for reporting the latest research on umbilical cord blood and tissue based therapies; engineering and manufacturing of cord blood immune cells; cord blood and cord tissue banking; the use of cord blood and cord tissue in regenerative medicine; and more. Under the leadership of section co-editors, Joanne Kurtzberg, MD, and Karen K. Ballen, MD, the Cord Blood section launches in early April with its first paper on the safety and feasibly of performing autologous umbilical cord blood infusions in young children with autism spectrum disorder.

The Cord Blood Association is excited and honored to partner with Stem Cells Translational Medicine to showcase the newest and highest quality translational and clinical applications of cord blood and cord tissue based therapies, said Dr. Kurtzberg. The mission and goals of both parties are aligned to maximize sharing of advances in these novel cell and tissue based therapies.

###

About Cord Blood Association: The Cord Blood Association will be an international nonprofit organization that promotes the banking and use of umbilical cord blood and related tissues for disease treatment and regenerative therapies.

About STEM CELLS Translational Medicine: STEM CELLS Translational Medicine (SCTM), published by AlphaMed Press, is a monthly peer-reviewed publication dedicated to significantly advancing the clinical utilization of stem cell molecular and cellular biology. By bridging stem cell research and clinical trials, SCTM will help move applications of these critical investigations closer to accepted best practices.

About AlphaMed Press: Established in 1983, AlphaMed Press with offices in Durham, NC, San Francisco, CA, and Belfast, Northern Ireland, publishes two other internationally renowned peer-reviewed journals: STEM CELLS (http://www.StemCells.com), celebrating its 35th year, is the world's first journal devoted to this fast paced field of research. The Oncologist (http://www.TheOncologist.com), also a monthly peer-reviewed publication, entering its 22nd year, is devoted to community and hospital-based oncologists and physicians entrusted with cancer patient care. All three journals are premier periodicals with globally recognized editorial boards dedicated to advancing knowledge and education in their focused disciplines.

Share article on social media or email:

Go here to see the original:
Cord Blood Association Names STEM CELLS Translational ... - PR Web (press release)

Posted in Cell Medicine | Comments Off on Cord Blood Association Names STEM CELLS Translational … – PR Web (press release)

Diabetes Product Solutions – HME Business (press release) (blog)

Posted: April 1, 2017 at 8:43 am

Diabetes Product Solutions

A look at some of the latest diabetes product offerings.

While the business of providing diabetes products and services has seen its fair share of obstacles competitive bidding slashing Medicare funding, private payer cuts, audits, customer retention, and the problem of low-quality devices on the market it still serves a critical market need.

The population of adults living with diabetes has quadrupled since 1980, growing to 422 million people, according to a report from the World Health Organization. A separate study by the Health Care Cost Institute showed that spending for children with diabetes who are covered by employer-sponsored insurance grew faster than any other age group. Clearly, there is a need for the devices just based on how many people in the United States must have them.

So how do diabetic supply providers keep ahead of these market trends? Their best bet for fostering business growth is to stock a wide variety of diabetes-related products that help you serve patients spectrum of needs. Manufacturers are doing a great job of providing products that cater to every aspect of a diabetic persons life. Good examples of related products would be items such as compression socks or diabetic footwear.

In addition to stocking up a well-rounded group of products, be sure to educate consumers on what the latest offerings are and how they can help them manage their condition. Learn about the customer and find out what their top concerns and priorities are, then assist them in finding the product or products that works best for them.

Compact and highly productive urine chemistry analyzer

ARKRAY Inc. (877) 538-8872 http://www.arkrayusa.com

Smart Blood Sugar connects to mobile phone

Bewellconnect (800) 250-7170 http://www.bewell-connect.us

Tie-less athletic shoes ensure comfort, protection

Orthofeet Inc. (800) 524-2845 http://www.orthofeet.com

Reduced friction, risk of infection for diabetes patients

SIGVARIS Inc. (800) 322-7744 http://www.sigvarisusa.com

Color coded results helps users manage care

LifeScan, Inc. (800) 227-8862 http://www.lifescan.com

Glucometer syncs into smartphones using audio

GlucoMe 972-3-372-8168 http://www.glucome.com

This article originally appeared in the April 2017 issue of HME Business.

About the Author

Sydny Shepard is the Products Editor for HME Business and Mobility Management and can be reached via email at SShepard@1105media.com.

Originally posted here:
Diabetes Product Solutions - HME Business (press release) (blog)

Posted in Diabetes | Comments Off on Diabetes Product Solutions – HME Business (press release) (blog)

Diabetes: Kids and Type 1 Diabetes – myfox8.com

Posted: April 1, 2017 at 8:43 am

Please enable Javascript to watch this video

The incidence of type 1 diabetes, previously known as juvenile diabetes, has been steadily rising in the United States. Type 1 diabetes is an auto-immune disease in which the body is destroying the cells in the pancreas that make insulin, and is often diagnosed in children and young adults. While the exact cause of type 1 diabetes is unknown, it most likely is triggered by a combination of genetic predisposition and environmental factors not diet or nutrition.

Diabetes is not an easy disease because it requires constant attention, its even more difficult for children to understand and to manage their own care properly. Most kids dont want to stand out among their peers or seem different and will minimize management of the disease at school or in front of their friends. It may take some time and adjustment, but advancements in the treatment of type 1 diabetes are allowing children who are diagnosed with the disease to live much more normal and high-quality lifestyles.

Signs of type 1 diabetes include weight loss, increased thirst and/or drinking, increased urination, increased appetite, and in some cases, vomiting, stomachaches, headaches and fatigue. These signs can often be mistaken for another illness, but if they persist, talk to your childs provider about testing their blood sugar levels. Everyone manages diabetes differently, and solutions that work for your child may not be the same as what works for someone else. The team of pediatric endocrinologists and medical support staff at Cone Health Pediatric Sub-Specialists of Greensboro is dedicated to educating children and families about diabetes and providing individualized treatment for children with the condition here in our community.

Spokesperson Background:

Dr. Ashley Jessup is a pediatric endocrinologist at Cone Health Pediatric Sub-Specialists of Greensboro and a member of Cone Health Medical Group. She received her Bachelor of Science in biology from North Carolina State University and completed medical school at the Brody School of Medicine at East Carolina University. Dr. Jessup completed her pediatric residency at nationwide Childrens Hospital in Columbus, Ohio and a pediatric endocrinology fellowship at the University of North Carolina Chapel Hill.

Here is the original post:
Diabetes: Kids and Type 1 Diabetes - myfox8.com

Posted in Diabetes | Comments Off on Diabetes: Kids and Type 1 Diabetes – myfox8.com

Youth with diabetes need vision loss screening | Reuters – Reuters

Posted: April 1, 2017 at 8:43 am

(Reuters Health) Diabetes can lead to blindness, but children and teens with diabetes may not receive recommended eye exams in the years following their diagnosis, a U.S. study suggests.

Researchers found that just 65 percent of youth with type 1 diabetes and 42 percent of those with type 2 diabetes had vision-loss screening within six years of their diabetes diagnosis.

More youth now than ever are being diagnosed with diabetes. By 2050, the prevalence with type 1 will triple and the prevalence with type 2 will quadruple, with the greatest increase in minority populations, said lead study author Dr. Sophia Wang of the University of Michigan Medical School in Ann Arbor.

The American Academy of Ophthalmology recommends screening for diabetic retinopathy five years after an initial diabetes diagnosis for youth with type 1 diabetes while the American Diabetes Association and the American Academy of Pediatrics recommend screening within three to five years. For kids with type 2 diabetes, screening is recommended at diagnosis.

Diabetic retinopathy is a complication of diabetes that may not have symptoms in early stages but can progress to vision loss. The damage to the retina of the eye results from damage to tiny blood vessels that affects other parts of the body as well.

About half of people with retinopathy develop diabetic macular edema, a fluid build-up in the retina, or glaucoma.

Diabetic retinopathy is the number one cause of vision loss in ages 20-74, so screening is an important component of diabetes care, Wang told Reuters Health by email.

To see how many kids with diabetes are getting the recommended screening, Wang and colleagues analyzed data from a national managed care network, which included more than 5,400 youth under age 21 with type 1 diabetes and 7,200 with type 2 diabetes.

Overall, researchers found that about 4,000 kids, or 31 percent, had an eye exam.

Those with type 1 diabetes were more likely to have had an eye exam compared with those who had type 2 diabetes, the study team reports in JAMA Ophthalmology . White and Asian youth were more likely to have had exams than black and Latino youth. Those with a higher household net worth were also more likely to receive an eye exam compared with those in lower-income households.

Despite the fact that all the youth in our study possessed health insurance, we found disparities by race and family affluence, suggesting that they may be particularly at risk, Wang said.

In the study, 11 percent of black children and teens and 18 percent of Latino youth were less likely to undergo an eye exam compared to white kids. Younger patients were also less likely to receive an exam than older ones.

We must educate adolescents and caregivers on the importance of screening to improve care coordination between different medical specialists such as pediatricians, endocrinologists, ophthalmologists and optometrists, said study author Dr. Joshua Stein of the University of Michigan Kellogg Eye Center in Ann Arbor.

More research is needed on new technologies which might render ophthalmic screening more accessible, such as retinal photography performed in primary care physicians clinics, he told Reuters Health by email.

Diabetic retinopathy is considered the most common microvascular complication of diabetes and is projected to grow at an alarming rate, said Dr. Seema Garg of the University of North Carolina at Chapel Hill, who wrote a commentary accompanying the study.

Visual impairment is detrimental to patients personal independence, economic productivity, employment and overall quality of life, she told Reuters Health by email. The opportunity costs of a lifetime of blindness are enormous.

Socioeconomics, geographical barriers, delayed referrals from primary care doctors, language barriers and cultural barriers also play a part in the screening gap. Retina screening via telemedicine could help address the issue, especially for racial minorities and economically disadvantaged youth, Garg writes in the commentary.

Telemedicine is an emerging strategy for improving screening with remote expert interpretation, she writes. Telemedicine is effective in reaching underserved populations in remote, rural or urban settings where patients may be at risk for more advanced disease.

SOURCE: bit.ly/2nAJHv1 and bit.ly/2nQkjn2 JAMA Ophthalmology, online March 23, 2017.

A federal judge in Delaware on Friday struck down key patents held by Acorda Therapeutics Inc related to its multiple sclerosis drug Ampyra, causing the stock to tumble 24 percent before trading was halted.

A U.S. patent board on Friday ruled against Danish drugmaker Forward Pharma A/S, finding Biogen's patents on its blockbuster multiple sclerosis drug Tecfidera to be valid.

Go here to see the original:
Youth with diabetes need vision loss screening | Reuters - Reuters

Posted in Diabetes | Comments Off on Youth with diabetes need vision loss screening | Reuters – Reuters

Arizona youth joins tribal officials to push for continued diabetes program funding – Arizona Capitol Times

Posted: April 1, 2017 at 8:43 am

A diabetic woman has her blood sugar tested. (Photo by Marcelo Camargo, Agencia Brasil/Creative Commons)

Alton Villegas offered an unusual call to action on March 29 for an 11-year-old boy: Destroy the ice cream man.

Alton is a member of the Salt River Pima-Maricopa Indian Community, where nearly 10 percent of tribal members have Type 2 diabetes, including members of his family.

My mom and my grandma have diabetes. A lot of people in Salt River have diabetes, sadly, said Alton, who has been diagnosed as pre-diabetic. I think a lot of people have diabetes because they dont eat healthy and they dont exercise.

Thats what brought Alton to Washington on March 29, where he was the youngest of six witnesses urging the Senate Indian Affairs Committee to reauthorize theSpecial Diabetes Programfor Native Americans.

Alton Villegas, 11, is a member of the Salt River Pima-Maricopa Indian Community, which is plagued by diabetes. He charmed a Senate committee with his own story at a hearing on saving tribal diabetes funding. (Photo by Marisela Ramirez/Cronkite News)

The program grants$150 milliona year to about 300 programs that push diabetes prevention to tribes in 35 states, said Rear Adm. Chris Buchanan, acting director of the Indian Health Service. If not reauthorized, the program will end after September.

Since the program began in 1997, tribal obesity rates have remained stubbornly high, said Sen. John Hoeven, R-North Dakota. He said Native Americans still have a greater chance of being diagnosed with Type 2 diabetes than any other group in America, and that diabetes is their fifth-leading cause of death.

But Hoeven, the committee chairman, also acknowledged atthe hearingthat the grants have helped lower diabetes and its complications, such as limb amputations, heart disease and kidney failure.

But theres still more work to be done, he added.

The Salt River Pima-Maricopa Indian Community, like other grantees, uses the funds to educate families about the benefits of exercise and balanced diet, and to offer free family-oriented exercise classes and programs that promote healthy lifestyles.

After a 6-year-old on the reservation was diagnosed with Type 2 diabetes about three years ago, the tribal council began more screening at schools and found 52 percent of students were above the 95th percentile for weight.

When a screening showed that Alton was at risk for Type 2 diabetes, his family learned that he qualified for theYouth Wellness Campin Prescott. Grant money from the federal program lets the tribe send at-risk youth to the camp.

I wanted to be healthier, so I went to camp, Alton said. I wanted to be able to help my mom and my grandma be healthier.

The healthy eating and daily exercise at camp helped Alton lose almost 16 pounds. His mother, Felicia Jimerson, said that Altons new outlook on eating healthy and exercising is rubbing off on her three other kids.

Alton said that he tries to help his family and friends make healthier decisions, but they do not always listen.

I tell them all the time but not a lot of people care, cause that means they have to give up Hot Cheetos, said Alton, who has seen his friends buy at least four bags of the snack a day from the ice cream man.

We must destroy the ice cream man! Altontold the committee,to laughter.

Rachel Seepie, another member of the Salt River Pima-Maricopa Indian Community who testified, credits some of her success against her Type 2 diabetes to educational programs funded by the grant program.

After initially managing her condition with medication, she decided to turn instead to exercise and eating well. That has helped her lose weight, lower her blood sugar, decrease her average heart rate and complete two Iron Man triathlons, Seepie said.

Now, she is a senior fitness specialist with the Diabetes Service Program and teaches group exercise classes on the reservation.

My vision is that the Salt River Pima-Maricopa Indian Community and our members will learn how to become healthier, and they will have long full lives without Type 2 diabetes, Seepie told the committee.

After the hearing, Jimerson said that can only happen if the grant program is reauthorized.

I think if they can continue that funding, its definitely going to make a change, she said. If that funding goes away, were in huge trouble.

Follow this link:
Arizona youth joins tribal officials to push for continued diabetes program funding - Arizona Capitol Times

Posted in Diabetes | Comments Off on Arizona youth joins tribal officials to push for continued diabetes program funding – Arizona Capitol Times

Eat 3 Servings Of This a Week to Cut Your Diabetes Risk By 35% – Men’s Health

Posted: April 1, 2017 at 8:43 am


Men's Health
Eat 3 Servings Of This a Week to Cut Your Diabetes Risk By 35%
Men's Health
After analyzing the food consumption of 3,349 people at high risk of heart disease but without type 2 diabetes, they discovered that those who ate about 3 servings a week of lentils, chickpeas, beans, and peas were 35 percent less likely to develop ...
Eat legumes to reduce your risk of type 2 diabetes by 35%Daily Mail
Eat legumes to cut the risk of Type 2 diabetesHindustan Times
Eating Legumes May Reduce Diabetes Risk by 35 Per CentNDTV
Malay Mail Online -Diabetes.co.uk
all 11 news articles »

Read more from the original source:
Eat 3 Servings Of This a Week to Cut Your Diabetes Risk By 35% - Men's Health

Posted in Diabetes | Comments Off on Eat 3 Servings Of This a Week to Cut Your Diabetes Risk By 35% – Men’s Health

New therapies show promise in treating diabetes – ModernMedicine

Posted: April 1, 2017 at 8:43 am

Diabetes medications were the most expensive traditional therapy drugs in 2016, with an overall trend of 19.4%, according to the latest Express Scripts drug trend report. This positive trend is reflective of increases in both utilization and cost.

Heres how pipeline developments could change the landscape.

Pipeline treatments

Peterson

While I do not see any game-changing medications within the diabetes class that will reach the market within the next several years, there are a few updates that we are watching, says Chris Peterson, director in the emerging therapeutics department at Express Scripts.

He points to the continued growth of the sodium-dependent glucose cotransporter-2 (SGLT-2) inhibitor classsparked by the positive cardiovascular outcomes from empagliflozin (Jardiance, Boehringer Ingelheim/Eli Lilly), a previously approved SGLT2 inhibitor. Pipeline SGLT-2 inhibitors include investigational ertugliflozin (Merck and Pfizer) and bexagliflozin (Chugai Pharma), both in phase 3 development at press time. Sotagliflozin (Lexicon Pharmaceuticals),a first-in-class oral dual SGLT-1 and SGLT-2 inhibitor for type 1 and type 2 diabetes, also in phase 3. If approved, it will be the first oral drug approved for type 1 diabetes, a disease that typically has been managed by lifestyle modifications and insulins, says Farrah Wong, PharmD, director, pipeline and drug surveillance at OptumRx.

Wong

The glucagon-like peptide-1 (GLP-1) analog class is also expected to grow, says Peterson. This is driven by cardiovascular outcomes data with liraglutide (Victoza, Novo Nordisk) and the introduction of the fixed-dose combination GLP-1 agonist/long-acting insulin products, insulin glargine and lixisenatide injection (Soliqua 100/3, Sanofi) and insulin degludec/liraglutide (Xultophy, Novo Nordisk).

Semaglutide is a GLP-1 agonist in development for glycemic control in patients with type 2 diabetes. It is being developed as both subcutaneous formulation from Novo Nordisk and oral form from Novartis. If approved, it will be the first oral GLP-1 agonist on the market.

As oral drugs are easier to administer and less invasive than injectable drugs, oral semaglutide may offer these advantages over other GLP-1 agonists, says Wong. Furthermore, type 2 diabetics will have another oral therapeutic option in a class of drugs that thus far were only injectable drugs.

Exenatide osmotic mini-pump (ITCA 650, Intarcia Therapeutics, Inc.) is a subcutaneous implant that continuously delivers the GLP-1 agonist, exenatide, for three months (introductory dose) or six months (maintenance dose) to treat type 2 diabetes. Approval is expected in November 2017, says Peterson.

New insulin products are also expected to receive approval soon, including insulin tregopil (Biocon Ltd.), an oral insulin in phase 2 development for type 1 and type 2 diabetes.

Currently, insulins are either injected or inhaled, says Wong. If an oral insulin product is available, the ease of administration may drive some of the market share to shift from injectable/inhaled insulins to the oral product.

Insulin glargine injection (Basaglar, Eli Lilly/Boehringer Ingelheim) approved last year, was the first follow-on insulin glargine product to treat diabetes. Another follow-on insulin glargine product, known as MK-1293 (Merck/Samsung Bioepis), will be competing as a brand product within the market and is expected to be approved in the second quarter of 2017. Basalog is yet another insulin glargine product currently in phase 3 development; however, it is not yet clear whether the manufacturer, Mylan, will seek approval as a competing brand or as a generic to Lantus (Sanofi). Finally, Sanofi is developing SAR342434, a follow-on protein to Lilly's Humalog (insulin lispro), for the treatment of diabetes mellitus. If approved, it will compete as a brand with the other rapid-acting insulins.

Link:
New therapies show promise in treating diabetes - ModernMedicine

Posted in Diabetes | Comments Off on New therapies show promise in treating diabetes – ModernMedicine

Page 1,621«..1020..1,6201,6211,6221,623..1,6301,640..»